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Abstract
Background: Hand, foot and mouth disease (HFMD) has become a major public health problem across the
Asia-Pacific region, and is commonly caused by enterovirus A71 (EV-A71) and coxsackievirus A6 (CV-A6), CV-A10 and
CV-A16. Generating pathogen whole-genome sequences is essential for understanding their evolutionary biology.
The frequent replacements among EV serotypes and a limited numbers of available whole-genome sequences
hinder the development of overlapping PCRs for whole-genome sequencing.
We developed and evaluated a non-ribosomal random PCR (rPCR) and next-generation sequencing based assay for
sequence-independent whole-genome amplification and sequencing of HFMD pathogens. A total of 16
EV-A71/CV-A6/CV-A10/CV-A16 PCR positive rectal/throat swabs (Cp values: 20.9–33.3) were used for assay
evaluation.
Results: Our assay evidently outperformed the conventional rPCR in terms of the total number of EV-A71 reads and
the percentage of EV-A71 reads: 2.6 % (1275/50,000 reads) vs. 0.1 % (31/50,000) and 6 % (3008/50,000) vs. 0.9 %
(433/50,000) for two samples with Cp values of 30 and 26, respectively. Additionally the assay could generate
genome sequences with the percentages of coverage of 94–100 % of 4 different enterovirus serotypes in 73 % of
the tested samples, representing the first whole-genome sequences of CV-A6/10/16 from Vietnam, and could
assign correctly serotyping results in 100 % of 24 tested specimens. In all but three the obtained consensuses of
two replicates from the same sample were 100 % identical, suggesting that our assay is highly reproducible.
Conclusions: In conclusion, we have successfully developed a non-ribosomal rPCR and next-generation sequencing
based assay for sensitive detection and direct whole-genome sequencing of HFMD pathogens from clinical samples.
Keywords: Hand, foot and mouth disease, Enterovirus A, Random PCR, FR26RV-Endoh primer, Next-generation
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Background
Hand, foot and mouth disease (HFMD) is a common
and usually mild disease of children worldwide. The
disease is caused by different genotypes of the species
Enterovirus A, genus Enterovirus, family Picornaviridae
(including coxsackievirus A (CV-A) 6, 10 and 16 and
particularly EV-A71). However, EV-A71 has emerged
and caused large and sometimes severe/fatal HFMD out-
breaks [1] across the Asia-Pacific region since 1997. Of
note, the frequent replacements between EV-As have
been observed over the last decade in the regions where
HFMD is endemic [2–6]. In recent years CV-A6 has
emerged and replaced CV-A16 to become the dominant
EV-A detected in HFMD patients [7, 8]. While the
underlying mechanism of this phenomenon remains
unknown, the data highlight the importance of contin-
ued effort to monitor the evolution of the causative
agents of HFMD.
Currently, there is no clinically proven antiviral drug
available to treat severe disease. Likewise, although
phase III trials of three monovalent inactivated EV-A71
vaccines have been completed in China with an efficacy
of over 95 %, routine use is still far away. Moreover, to
what degree the implementation of a monovalent vac-
cine for EV-A71 may influence the epidemic patterns of
HFMD and the evolution of the causative agents in
endemic countries is a subject that merits follow-up
research.
Collectively, the ability to generate viral whole-genome
sequences is essential for understanding the evolutionary
biology and epidemiology of HFMD. It is also important
for the development of intervention strategies, especially
vaccines. While the availability of relatively large num-
bers of EV-A71 whole-genome sequences (n = ~524)
deposited in GenBank has facilitated the development of
a sensitive overlapping PCR based whole-genome se-
quencing assay [9], smaller numbers of whole-genome
sequences of other EV-As are available (CV-A16; n = 61,
A6; 35, A10; 11) from limited localities. This is problem-
atic for the selection of specific PCR primers that can
amplify diverse EV-As. Additionally, one of the major
drawbacks of specific-PCR based sequencing assays is
that due to the nature of quick evolution rates of RNA
viruses, selected primers may need to be adjusted regu-
larly to be able to amplify newly emerging viral variants or
genotypes. As a consequence, a sequence-independent
approach is thus attractive to overcome such obstacles.
Developed by Froussard in 1992 [10], random PCR
(rPCR) primer (FR26RV-N6: 5′-GCCGGAGCTCTGCA
GATATCNNNNNN-3′) consists of a fixed 20 nucleo-
tides (FR20RV: GCCGGAGCTCTGCAGATATC) at the
5′-end and a random hexanucleotides at 3′ end (N6:
NNNNNN). In 2005 Endoh and his colleagues designed
a set of 96 hexanucleotides for specific amplification of
viral sequences called non-ribosomal hexanucleotides
[11]. For sequence-independent whole-genome amplifi-
cation and sequencing of HFMD pathogens, herein we
describe the development and evaluation of a non-
ribosomal random amplification assay utilizing the 96
non-ribosomal hexanucleotide oligos designed by Endoh
[11] and the 5′-end fixed oligo of the conventional ran-
dom PCR primers (FR20RV) [10]. When combined with
next-generation sequencing, our assay showed that it
could generate full-genome sequences of HFMD patho-
gens directly from clinical specimens.
Methods
Samples
The clinical samples used included two residual throat
swabs from anonymous HFMD patients with EV-A71
infection admitted to the Hospital for Tropical Dis-
eases in Ho Chi Minh City in 2012. Additionally, 13
throat/rectal swabs of diverse viral load (including CV-
A6; n = 4, CV-A10; n = 4, CV-A16; n = 3 and EV-A71;
n = 2) derived from patients enrolled into an on-going
prospective observational HFMD study of all severities
in three referral hospitals in Ho Chi Minh City,
Vietnam since 2013 were also used [9]. The clinical
samples were collected in viral transport medium,
divided into three aliquots and stored at -80 °C until
use. Viral detection and serotype identification were
done as per the study protocol using previous de-
scribed assays [12, 13].
Development and preparation of non-ribosomal random
PCR primers
For selective amplification of viral sequences, we re-
placed the random hexanucleotide motif at the 3′-end of
the primer FR26RV-N6 by those 96 hexanucleotides
designed by Endoh. This resulted in a set of 96 separate
primers consisting of an FR20RV sequence at 5′-end
plus one of the 96 Endoh’s hexanucleotides at the 3′-end
(Additional file 1: Table S1).
Each individual primer was synthesized at a concentra-
tion of 100 μM, and an equal amount of each synthesized
oligo was pooled together to make working solution
(~1 μM). This primer mixture was named FR26RV-Endoh.
Sample pretreatment and nucleic acid extraction
An overview of the whole procedure is described in
Fig. 1. Sample pretreatment was carried out as previ-
ously described [14]. In short, prior to nucleic acid isola-
tion 110 μl of clinical samples was centrifuged at
10,000 g for 10 min. The resulting 100 μl of superna-
tants were collected and treated with 2U/ul of turbo
DNase (Ambion, Life Technology, Carlsbad, CA, USA)
at 37 °C for 30 min. Viral RNA was then extracted
from the treated material using QIAamp viral RNA kit
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(QIAgen GmbH, Hilden, Germany), following the man-
ufacturer’s instructions, and finally eluted in 50 μl of
elution buffer (provided with the extraction kit).
cDNA and double stranded DNA synthesis
Double stranded (ds) DNA was synthesized from the
extracted RNA using either FR26RV-N6, FR26RV-Endoh,
random hexanucleotides or non-ribosomal \hexanucleotides
primer. Firstly, 10 μl of extracted RNA was mixed with
0.1 μM of the primer and 0.5nM of dNTPs (Roche Diag-
nostics GmbH, Mannheim, Germany). The mixture was
incubated at 65 °C for 5 min, and was then immediately
chilled on ice for 1 min. Secondly, 7 μl of a reaction mix
containing 200U of Super Script III, 40 U of RNase OUT,
0.1 M DTT and 1X first strand buffer (Invitrogen, Carlsbad,
CA, USA) was added into the first reaction mixture. The
reaction was continued at 25 °C for 10 min, 37 °C for 1 min
and 94 °C for 2 min, and then immediately chilled on ice
for 2 min. Next, 5U of exo-Klenow fragment (Ambion) and
10U of Ribonuclease H (Ambion) were added into the reac-
tion mixture, which was finally subjected to a double-
stranded (ds) DNA synthesis step consisting of 25 °C for
5 min, 37 °C for 1 h and 75 °C for 10 min.
Random amplification
The resulting dsDNA products generated by FR26RV-
N6 and FR26RV-Endoh primers were amplified using
FR20RV primer (5′-GCCGGAGCTCTGCAGATATC-3′).
PCR amplification was carried out in a total reaction vol-
ume of 50 μl consisting of 3 μl of dsDNA, 0.4 μM of pri-
mer FR20RV and 45 μl of Platinum PCR supermix high
fidelity (Invitrogen). The thermal cycling condition con-
sisted of 94 °C for 2 min and followed by 40 cycles of 94 °C
for 30s, 55 °C for 30s and 72 °C for 3 min and 1 cycle of
72 °C for 2 min.
Next generation sequencing library preparation and
sequencing
The resulting dsDNA generated by hexanucleotides or
non-ribosomal hexanucleotides and rPCR products
were purified with use of QIAquick PCR purification
kit (QIAgen GmbH, Hilden, Germany). DNA concen-
tration of the purified products was measured by
Qubit dsDNA HS kit (Invitrogen). One nanogram of
the purified DNA was then subjected to library prep-
aration steps by using Nextera XT DNA library prep-
aration kit (Illumina, San Diego, CA, USA), according
to manufacturer’s instructions. Prior to sequencing,
the quantity of the prepared library was measured by
using KAPA Library Quant Kit (Kapa Biosystems,
Wilmington, MA, USA), following manufacturer’s
instructions.
The prepared library was sequenced using MiSeq
reagent kit V2 in an Illumina Miseq platform (Illumina).
For each run, tested samples were multiplexed and dif-
ferentiated by double indexes using Nextera XT Index
Kit (Illumina).
Sequence analysis
The sequences generated by Illumina Miseq were ana-
lyzed using Geneious 8.1.5 (Biomatters, San Francisco,
CA, USA). The obtained sequences were processed to
remove primer sequences. Sequence assembly was car-
ried out by using a reference-based mapping strategy
available in Geneious (CV-A10, HQ728262; CV-A6,
JN582001; CV-A16, JX481738; EV-A71 B5, DQ341363;
EV-A71 C4, AB550338), followed by manual editing of
the obtained consensus.
Representatives of viral protein 1 (VP1) sequences of
CV-A16 (n = 39), A6 (38), A10 (29) and EV-A71 (36) of
different subgenotypes and from various localities world-
wide were used for phylogenetic inference. Pairwise
alignment was performed using Geneious alignment
tool. Phylogenetic reconstructions were performed using
maximum likelihood method (ML) with general time
reversible (GTR) nucleotide substitution model available
in Geneious package, and support for individual nodes was
assessed using a bootstrap procedure (1000 replicates).
The sequences obtained in this study were submitted
to NCBI (GenBank) and assigned accession numbers
KX430795-KX430824.
Fig. 1 Flowchart showing an overview of the whole procedure of
rPCR-Miseq based assay. Note: * the turn-around time may vary,
especially when using service platform, which may take more
than 2 days
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Results
Non-ribosomal rPCR vs. conventional rPCR
To test whether our modified rPCR, which we named
non-ribosomal rPCR, can selectively amplify viral se-
quences in clinical specimen as compared to the con-
ventional rPCR, two EV-A71 positive swabs with Cp
values of 26 (ID.13) and 30 (ID.14) (i.e. high and low
viral load) were selected and subjected to random ampli-
fication procedures utilizing either FR26RV-N6 or
FR26RV-Endoh, and followed by Illumina Miseq sequen-
cing. The total- and percentage of EV-A71 reads, gen-
ome coverage and sequencing depth/coverage (i.e. the
number of times a single nucleotide was sequenced)
were taken into account for comparison.
In order to avoid the potential biases introduced by
variable number of reads between barcodes, a total of
50,000 reads were randomly taken from each index for
the analysis. In both tested EV-A71 positive samples, the
total number of EV-A71 reads and the percentage of
EV-A71 reads generated by non-ribosomal rPCR based
assay was higher than the corresponding outputs gener-
ated by the conventional rPCR-based assay; 2.6 % (1275/
50,000 reads) vs. 0.1 % (31/50,000 reads) for the sample
ID14 with Cp value of 30 and 6 % (3008/50,000 reads)
vs. 0.9 % (433/50,000 reads) for the sample ID13 with
Cp value of 26 (Fig. 2). Additionally, a higher EV-A71
genome coverage and sequencing depth were also ob-
served in both samples sequenced by non-ribosomal
rPCR-based assay (Fig. 3). Taken together, the data indi-
cated that our non-ribosomal rPCR is more viral specific
and efficient than the conventional rPCR.
Non-ribosomal rPCR vs. direct sequencing
Previous studies shown that viral load enrichment by
random amplification step resulted in biases in genome
coverage [15, 16]. We therefore further evaluated our
non-ribosomal rPCR by comparing its performance
against that of direct sequencing of dsDNA library gener-
ated by hexanucleotide or non-ribosomal hexanucleotide
primers. An EV-A71 positive throat swab (sample ID15)
with a Cp value of 31 was used. After normalization, the
obtained reads of each DNA library were map to an EV-
A71 genome (DQ341363.1). Despite biases in terms of
sequencing depth across the genome, non-ribosomal
rPCR based workflow could generate nearly complete EV-
A71 genome sequence (KX430823), while dsDNA library
produced by hexanucleotide and non-ribosomal hexanu-
cleotide primers could not (Additional file 1: Figure S1).
Detection and sequencing of HFMD pathogens:
assessment of assay sensitivity and reproducibility
To further evaluate the performance of our non-
ribosomal rPCR assay in terms of sensitivity and reprodu-
cibility a series of 12 swabs that were EVs real time PCR
positive with different common HFMD pathogens (includ-
ing CV-A6, CV-A10, CV-A16 and EV-A71) and with a
wide range of Cp values from 20.8 to 33.3 [12] (i.e. from
high to low viral load) (described in Methods section)
were included for testing (Table 1). The included samples
were tested in duplicate from sample pretreatment to
nucleic acid isolation, random amplification by FR26RV-
Endoh primers and sequencing by Illumina Miseq, resulting
a total of 24 MiSeq datasets (Table 1).
Assay sensitivity
Illumina Miseq sequencing results showed that in
addition to successfully providing correct serotype infor-
mation (i.e. diagnostic results) in 100 % (24/24) of the
tested samples, the assay could generate 17/24 (71 %)
genome sequences of HFMD pathogens with the per-
centages of coverage of between 94 and 100 % (Table 1).
Collectively, of 24 tested samples, whole-genome
sequencing success rates of 100 % (8/8), 93 % (13/14)
and 71 % (17/24) with genome coverage of 94-100 %
without internal gap were achieved among samples with
Cp values of ≤25, ≤30 and ≤33.3, respectively (Table 1).
Assay reproducibility
To investigate the reproducibility of the assay, we com-
pared the level of sequence identity between the
obtained consensuses of the tested sample and its repli-
cate. In 9/12 tested samples the consensuses of both
Fig. 2 Percentages of EV-A71 reads (in orange) generated by
conventional rPCR (a for sample ID13 (Cp value: 26) and c; ID14 (Cp
value: 30)) and by non-ribosomal rPCR (b; ID13 (Cp value: 26) and d;
ID14 (Cp value: 30))
Nguyen et al. Virology Journal  (2016) 13:125 Page 4 of 10
replicates were 100 % identical (Table 1). In the remaining
3 samples, the differences of between 0.01 - 0.04 % were
recorded (Additional file 1: Table S2). Additionally, the
level of genome coverage, mean coverage (i.e. the numbers
of times that a single nucleotide was sequenced) and the
percentage of viral reads were comparable between two
replicates (Table 1).
Phylogenetic analysis
Currently there are relatively few whole-genome se-
quences of CV-A6, CV-A10 and CV-A16 from limited
geographical localities available in GenBank. To make
more meaningful phylogenetic inference, we therefore first
focused our analysis on representative VP1 sequences
collected from different geographic locations worldwide.
Phylogenetic analysis of VP1 sequences suggested that
the EV-A71 strains obtained in the present study sam-
pled in 2012 belonged to subgenogroup C4, whereas the
viruses collected in 2013 belonged to subgenogroup B5
(Additional file 1: Figure S1), which reconfirmed our
previous finding about the replacement between these
two subgenogroups occurring in Vietnam around 2012
[17]. All CV-A16 sequences belonged to genogroup B1a.
In Vietnam, this B1a genogroup was first detected in the
2005 outbreak [18] and showed a close relatedness to
the viruses circulating in the Asia-Pacific region (e.g.
China, Japan, Thailand and Malaysia) (Additional file 1:
Figure S2). In contrast, the analysis of CV-A6 sequences
indicated that our CV-A6 belonged to genogroup A,
which consists of CV-A6 strains sampled from United
Kingdom and others viruses from China and Taiwan
(Fig. 4b). Likewise, the CV-A10 strains sequenced in the
present study belonged to genogroup C consisting of
viral trains originating from various parts of the world
and associated with HFMD outbreaks in Europe and
Asia including in Spain, France and China (Fig. 4a).
Similar results in terms of phylogenetic clustering of the
sequences were obtained when whole-genome sequences
were analyzed separately (data not shown).
Discussion
Traditionally, obtaining whole-genome sequence of a
pathogen requires the design of several overlapping
specific PCR primers based on the basis of sequence
alignment of the published genome sequences. Although
such strategies have been successfully applied for se-
quencing of HFMD pathogens including EV-A71 and
other EV-As [9, 19–21], except for EV-A71, these
Fig. 3 Screen snapshots showing coverage of mapping EV-A71 reads to reference genome, a for sample ID13 with a Cp value of 26; non-ribosomal
rPCR (lower panel) vs. conventional rPCR (upper panel) and b sample ID14 with a Cp values of 30. The genome coverage/sequencing depth is
indicated by the Y axis and covered by red circles, and orange lines highlight the sequencing depth of 2 or more
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Table 1 Result summary of non-ribosomal rPCR and Miseq run






Mean coverage Accession numbers Pairwise
identity (%)
CV-A6 1 RS 22.69 90.2 99.5 0 26542 KX430795 100
85.1 100 0 22630 KX430796
2 TS 28.34 11.2 97.5 0 1173 KX430797 100
10.9 95.3 0 1119 KX430798
3 RS 30.5 7.9 97.7 0 1822 KX430799 100
8.3 97.3 57 2244 KX430800
4 TS 32.06 7.1 75 1625 1328 KX430801 99.96
13.3 96.8 41 3061 KX430802
CV-A10 5 RS 20.92 40.7 99.2 0 11189 KX430803 100
53.8 98 0 12725 KX430804
6 RS 23.59 53.1 97.5 0 17439 KX430805 100
51.9 97.6 0 14086 KX430806
7 RS 26.71 18.2 98 0 4299 KX430807 99.99
14.5 97 0 3820 KX430808
8 TS 33.2 42.4 94 0 12216 KX430809 99.99
30.5 97.2 26 8412 KX430810
CV-A16 9 TS 24.97 83.8 99.7 0 3161 KX430811 100
80.1 99 0 20597 KX430812
10 TS 26.72 2 91 71 475 KX430813 100
2.1 96 0 509 KX430814
11 TS 33.26 4.5 96 0 971 KX430815 100
4.2 86 712 1101 KX430816
EV-A71 12 TS 31.1 0.2 72.5 1447 5.3 KX430817 100
0.3 94 0 52.6 KX430818
aMiseq run was multiplexed. Only run output of relevant samples were shown here; CV-A6: coxsackievirus A6, CV-A10: coxsackievirus A10, CV-A16: coxsackievirus A16 and EV-A71 B5: enterovirus A71 subgenogroup B5;










overlapping primers were designed based on a limited
numbers of sequences of EV-As and therefore may not
function properly on diverse circulating viral strains
whose complete genomes are yet to be sequenced. In
addition, to be able to amplify emerging outbreak/novel
strain, such viral specific PCR primers often need to be
updated regularly, which is always challenging.
There have been several reports regarding the use of
random primers, e.g. FR26RV-N6 primer, to generate
whole-genome sequence of viral pathogens [22, 23].
However, as FR26RV-N6 primer contains a random
hexamer motif at the 3′ end, which is not viral specific,
assays may therefore lack specificity when used on
materials such as rectal/throat swabs, which contain
high amounts of host genetic materials and low con-
centrations of targeted virus. Meanwhile, Endoh’s non-
ribosomal hexanucleotide oligos have recently been
successfully used as an alternative to random hexamers
for selective amplification of viral RNA in the field of
viral pathogen discovery [24–26]. For specific amplifi-
cation and sequencing of viral pathogens in particular
HFMD viruses (which were the focus of the present
study) in clinical specimens, we adapted the fixed 5′
end oligo of the normal random PCR and Endoh’s non-
ribosomal hexanucleotides to create a novel 96 viral
specific rPCR primer set (Additional file 1: Table S1).
When compared back-to-back using EV-A71 positive
swabs, our non-ribosomal rPCR evidently outperformed
the normal rPCR utilizing FR26RV-N6 primers and
direct sequencing of dsDNA libraries generated by either
hexanucleotides or non-ribosomal hexanucleotides. In
subsequent testing we showed that without the require-
ment of viral specific PCR, our assay could generate
whole-genome sequences of 4 different common HFMD
pathogens (including CV-A6, CV-A10, CV-A16 and EV-
A71) in either rectal or throat swabs with diverse viral
load. Of 24 tested samples with Cp values between 20.9
and 33.2, (nearly) complete genomes were obtained in
17/24 (71 %) samples, representing the first whole-
genome sequences of CV-A6, CV-A10 and CV-A16
from Vietnam. In three tested swabs and their replicates,
the obtained consensuses occupied between 0.01–0.04 %
of differences. This is however below the reported error
rate of next generation sequencing (0.1 %). Of note, 2
out of the 4 EV-A71 genomes sequenced in the present
study (sample IDs: 13 and 15) were previously recovered
(KJ686266 and KX430824) using an overlapping PCRs
and deep sequencing based workflow [9, 17]. And
Fig. 4 The Maximum likelihood phylogenetic trees based on completed VP1 nucleotide sequences obtained in this study and representatives of
VP1 sequences retrieved from GenBank. a ML phylogeny of VP1 sequences (894 nt) of CV-A10 strains (n = 54); b ML phylogeny of VP1 sequences
(915 nt) of CV-A6 strains (n = 60). Scale bars indicated numbers of nucleotide substitution per site. CHN, China; FRA, France; ESP, Spain; US, United
states; IND, India; Fin, Finland; JPN, Japan; TW, Taiwan; UK, United Kingdom; VN, Vietnam
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pairwise comparisons of the obtained consensuses gen-
erated by both workflows revealed only 0.03 % and
0.04 % of variations without amino acid substitution
observed (data not shown). Collectively, the data points
to the fact that potential biases (if any) introduced by
enrichment steps as 40-cycle PCR amplification by
FR20RV primer of the present workflow is negligible
and that our non-ribosomal rPCR and next-generation
based assay is reproducible and sensitive.
Despite the use of non-ribosomal primers and the
employment of a sample pretreatment step incorporating
centrifugation and DNase treatment to enrich for enterovi-
ral content in the swabs, the percentage of enteroviral
reads in the obtained MiSeq libraries ranged between 0.2
and 90.2 %. This might have been attributed to the differ-
ence in terms of the compositions of non-enteroviral
contents between the samples and/or the viral load of the
tested viruses. Meanwhile there have been other reports
about alternative sequence-independent whole-genome
next-generation sequencing based assays including those
incorporating sample pretreatment steps as physical virion
enrichment and RNase digestion [27–29]. It is therefore of
interest to evaluate the usefulness of those sample pre-
treatment steps when combined with our non-ribosomal
rPCR. Likewise, comparing the performance of our non-
ribosomal rPCR with those existing sequence-independent
assays warrants further research, which is however beyond
the scope of the present study.
For clinical diagnostics, obtaining partial viral genome
sequence is sufficient for establishment of the diagnostic
result. Exploring the use of next-generation sequencing
based assay as a diagnostic tool was an objective in many
recent reports [30–32]. In addition, next-generation
sequencing has been shown to be able to establish the
diagnostics in swabs from HFMD patients that were
enterovirus specific PCR negative [33]. Similarly, our
assay could sequence and provide correct serotype infor-
mation of the targeted enteroviruses in all tested samples
with Cp values between 20.9 and 33.2, although we did
not test our assay on samples with lower viral load (i.e.
Cp value of >33.2). Assuming that a Cp value of 33.2 is
the assay limit of detection, and a Cp value of <30 is
required for the purpose of whole-genome sequencing;
among a sample collection from over 1300 HFMD
patients enrolled in our ongoing HFMD study in Ho Chi
Minh City, Vietnam (data not shown), we can conserva-
tively extrapolate that our assay can detect enterovirus
in 97 % and generate complete or nearly complete gen-
ome sequence of enteroviruses in 62 % of the RT-PCR
positive clinical samples, respectively.
The advantages of random amplification and NGS based
assay include: i) there is no requirement for several patho-
gen specific assays to diagnose diseases caused by multiple
pathogens as HFMD, and ii) in addition to providing
diagnostic information, the obtained sequencing result is
informative for study of viral evolution and identification
of the source of an outbreak. Indeed, by analyzing the
obtained sequences we were able to reveal interesting
insights into the evolution and origin of the CV-A6, CV-
A10, CV-A16 and EV-A71 in Vietnam, albeit the sample
size was small. As a consequence, further effort to obtain
full genome sequences of HFMD causing pathogens is
currently ongoing as part of our HFMD research program,
which ultimately would lay the foundation for future
research focusing on genetic diversity and evolutionary
dynamics of HFMD in Vietnam and beyond, and can now
be facilitated by our viral specific rPCR and next-
generation sequencing based assay.
Our study has some limitations: i) we only evaluated
our assay performance on rectal/throat swabs, whereas
in HFMD, viral detection in vesicle swab, blood, CSF
and urine has been reported, albeit at a lower frequency
in the latter 3 sample types. Evaluation of the assay on
these sample types is therefore needed, ii) similar to
other reports [15, 16], we observed that the level of
sequencing depth varied across the genomes of the
tested viruses generated in the present study. While in
silico investigation did not reveal any biases in terms of
binding preference of the non-ribosomal hexanucleo-
tides to specific genomic regions of the targeted viruses,
it is attempting to speculate that such biases were attrib-
uted to the transposome-based library workflow as pre-
viously reported [34], iii) the current high cost (~$USD
75 per sample as compared to $USD 5–8 per one mono-
plex PCR reaction), low throughput (total operation time
is about 5 days to complete) and bioinformatics require-
ments remain major barriers for next-generation
sequencing-based assays to be widely applied in a diag-
nostic setting, in particular in less developed countries
in Asia where HFMD is endemic, iv) the capacity of
rPCR and next generation sequencing based assay to
detect mixed infection and to identify novel/new viral
variants [27, 35, 36] was not explored as it is beyond the
scope of this study. For the latter, de novo assembly
approach followed by metagenomic analysis using
appropriate bioinformatics tool is recommended. Like-
wise, evaluating the viability of the 96 non-ribosomal
hexanucleotides on new viral species discovered from
2005 onward is needed.
Conclusion
We have successfully developed a non-ribosomal rPCR
and next-generation sequencing based assay for sensitive
detection and whole-genome sequencing of HFMD
pathogens in clinical samples. Our assay can be used to
study the genetic diversity and evolutionary biology of
HFMD pathogens, which may aid the development of
intervention strategies (including vaccines), and guide
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public health plans in response to future HFMD out-
breaks. As next-generation sequencing associated cost
has been going down quickly, and once the bioinformat-
ics challenge becomes less burden, one would expect the
expanding use of next-generation sequencing based
methodologies in clinical research and routine care, both
in developed and less developed countries.
Additional file
Additional file 1: Table S1. List of 96 FR26RV-Endoh and FR20RV
primer sequences. Table S2. Result summary of consensus sequence
variations recorded between 2 replicates of 3 tested swabs. Note: NA: not
applicable. Figure S1. Screen snapshots showing the mapping results of
EV-A71 MiSeq reads to an EV-A71 reference genome of sample ID15;
non-ribosomal rPCR assay (bottom panel), non-ribosomal hexanucleotide
primers assay (middle panel) and hexanucleotide assay (top panel); the
genome sequencing depth is indicated by the Y axis and covered by red
circles. Figure S2. Maximum likelihood phylogenetic tree based on
completed VP1 nucleotide sequences (891 nt) of EV-A71 strains obtained
from this study (in bold red) and representatives retrieved from GenBank.
Scale bars indicated numbers of nucleotide substitution per site. CHN,
China; USA, United states; TW, Taiwan; NL, Netherlands; MY, Malaysia;
KOR, Korean; VN, Vietnam. Figure S3. Maximum likelihood phylogenetic
tree based on completed VP1 nucleotide sequences (891 nt) of CV-A16
strains obtained from this study (in bold red) and representatives
retrieved from GenBank. Scale bars indicated numbers of nucleotide
substitution per site. CHN, China; US, United states; TL, Thailand; JPN,
Japan; AUS, Australia; MY, Malaysia; KOR, Korean; VN, Vietnam.
(PDF 783 kb)
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